BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; skin cancer Blocking endocytosis with DMN inhibitors could enhance the efficacy of cetuximab, trastuzumab and Bavencio avelumab against skin, breast and colorectal cancers. The mAbs target EGFR,...
BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit  Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Metabolite scavengers to resensitize K-Ras-mutant colorectal cancer to Erbitux

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Scavengers of the glycolysis metabolite methylglyoxal could resensitize K-Ras-mutant colorectal cancer to Erbitux cetuximab. In patients, levels of methylglyoxal adducts were higher in tumors with K-Ras G12V mutations than...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...
BC Extra | Dec 20, 2019
Company News

Regulatory roundup: Gilead, BMS seeking key approvals, plus news about AbbVie, Bavarian Nordic and more

A basket of regulatory news this week included submissions of closely watched products from Gilead and BMS, including the first-ever NDA for a candidate from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Gilead Sciences Inc. (NASDAQ:GILD) is seeking...
BC Innovations | Oct 24, 2019
Tools & Techniques

Driving safely into solid tumors with CAR exosomes

Therapeutic exosomes derived from CAR T cells could avoid the cytotoxic side effects of the engineered cells and overcome barriers in the tumor microenvironment that limit the cells’ efficacy. The obstacles to deploying CAR T...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BioCentury | Aug 3, 2019

Pfizer needs to prove it's a growth story

With shares of Pfizer trading near a 52-week low in the wake of its deal with Mylan, the pharma will need to show the market that it is indeed a growth story if it hopes...
BC Extra | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
Items per page:
1 - 10 of 1092